Industry and MASCC-an opportunity not to be missed

Joel B Epstein¹, David R Dean², Stephen T Sonis^{3

4}

Affiliations

¹ City of Hope Comprehensive Cancer Center, Duarte CA and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical System, Los Angeles, CA, USA. jepstein@coh.org.
² Seattle Cancer Care Alliance/University of Washington, Seattle, WA, USA.
³ Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Biomodels, LLC and Primary Endpoint Solutions, Waltham, MA, USA.

Editorial

Joel B Epstein et al. Support Care Cancer. 2021 Feb.

. 2021 Feb;29(2):559-561.

doi: 10.1007/s00520-020-05894-z.

Joel B Epstein¹, David R Dean², Stephen T Sonis^{3

4}

¹ City of Hope Comprehensive Cancer Center, Duarte CA and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical System, Los Angeles, CA, USA. jepstein@coh.org.
² Seattle Cancer Care Alliance/University of Washington, Seattle, WA, USA.
³ Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Biomodels, LLC and Primary Endpoint Solutions, Waltham, MA, USA.

No abstract available

References

1. Moharty R et al (2019) CAR T cell therapy: a new era for cancer treatment (review). Oncol Rep 42:2183–2195
1. Gougis P et al (2019) Clinical development of molecular targeted therapy in head and neck squamous cell carcinoma. JNCI Cancer Spectr 3:pkz055. https://doi.org/10.1093/jncics/pkz055 - DOI - PubMed - PMC
1. Morgan HE, Sher DJ (2020) Adaptive radiotherapy for head and neck cancer. Cancers Head Neck 5:1. https://doi.org/10.1186/s41199-019-0046-z - DOI - PubMed - PMC
1. Carlisle JW, Steuer CE, Owonikoko TK, Saba NF (2020) An update on the immune landscape in lung and head and neck cancers. CA Cancer J Clin. https://doi.org/10.3322/caac.21630
1. Dhodapkar KM (2019) Autoimmune complications of cancer immunotherapy. Curr Opin Immunol 61:54–59 - DOI